Risk of new primary malignancies with denosumab

Risk of new primary malignancies with denosumab Reactions 1704, p4 - 2 Jun 2018 Risk of new primary malignancies with denosumab Patients with advanced malignancies who receive denosumab (Xgeva) are at risk of developing new primary malignancies, says Amgen. In agreement with the EMA and Ireland’s Health Products Regulatory Authority, Dr Anthony Patrikios from Amgen (Executive Medical Director, UK & Ireland) issued a ’Dear Healthcare Professional’ letter advising of this new safety concern. Data from a pooled analysis of four phase III studies revealed that more patients with advanced malignancies treated with Xgeva reported a new primary malignancy (1.5%), compared with those treated with zoledronic acid (0.9%). In addition, the cumulative incidence of new primary malignancies at 1 year was higher in Xgeva-treated patients (1.1%), compared with zoledronic acid-treated patients (0.6%). Dr Patrikios also noted that "no treatment-related pattern in individual cancers or cancer groupings was apparent". Information regarding this risk of new primary malignancy will be added to the Xgeva product information. Patrikios A. Risk of New Primary Malignancy with Xgeva (denosumab): Direct Healthcare Professional Communication. Internet Document : [2 pages], 16 May 2018. Available from: URL: http://www.hpra.ie/docs/default-source/default- document-library/ 803324520 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Risk of new primary malignancies with denosumab

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/risk-of-new-primary-malignancies-with-denosumab-epoW0z0yVL
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46647-8
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p4 - 2 Jun 2018 Risk of new primary malignancies with denosumab Patients with advanced malignancies who receive denosumab (Xgeva) are at risk of developing new primary malignancies, says Amgen. In agreement with the EMA and Ireland’s Health Products Regulatory Authority, Dr Anthony Patrikios from Amgen (Executive Medical Director, UK & Ireland) issued a ’Dear Healthcare Professional’ letter advising of this new safety concern. Data from a pooled analysis of four phase III studies revealed that more patients with advanced malignancies treated with Xgeva reported a new primary malignancy (1.5%), compared with those treated with zoledronic acid (0.9%). In addition, the cumulative incidence of new primary malignancies at 1 year was higher in Xgeva-treated patients (1.1%), compared with zoledronic acid-treated patients (0.6%). Dr Patrikios also noted that "no treatment-related pattern in individual cancers or cancer groupings was apparent". Information regarding this risk of new primary malignancy will be added to the Xgeva product information. Patrikios A. Risk of New Primary Malignancy with Xgeva (denosumab): Direct Healthcare Professional Communication. Internet Document : [2 pages], 16 May 2018. Available from: URL: http://www.hpra.ie/docs/default-source/default- document-library/ 803324520 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off